1. Home
  2. KSCP vs SCYX Comparison

KSCP vs SCYX Comparison

Compare KSCP & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Knightscope Inc.

KSCP

Knightscope Inc.

HOLD

Current Price

$2.00

Market Cap

58.1M

ML Signal

HOLD

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$3.82

Market Cap

60.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KSCP
SCYX
Founded
2013
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
58.1M
60.4M
IPO Year
2022
2014

Fundamental Metrics

Financial Performance
Metric
KSCP
SCYX
Price
$2.00
$3.82
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
1
Target Price
$17.00
$3.00
AVG Volume (30 Days)
599.8K
188.8K
Earning Date
05-12-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
63.54
61.36
EPS
N/A
N/A
Revenue
$11,335,000.00
$257,000.00
Revenue This Year
$218.66
N/A
Revenue Next Year
$54.32
$608.78
P/E Ratio
N/A
N/A
Revenue Growth
4.91
N/A
52 Week Low
$1.88
$0.57
52 Week High
$10.13
$5.62

Technical Indicators

Market Signals
Indicator
KSCP
SCYX
Relative Strength Index (RSI) 31.79 61.55
Support Level N/A $0.67
Resistance Level $3.17 $5.62
Average True Range (ATR) 0.17 0.34
MACD -0.01 -0.12
Stochastic Oscillator 21.02 14.39

Price Performance

Historical Comparison
KSCP
SCYX

About KSCP Knightscope Inc.

Knightscope Inc is a security technology company based in Silicon Valley. It designs, develops, manufactures, markets, and supports Autonomous Security Robots (ASRs), autonomous charging stations, the proprietary Knightscope Security Operations Center software user interface, Emergency Communication Devices platform with real-time on-site data collection and analysis and a proprietary interface for both indoor and outdoor usage. In addition, it developed and operates the Knightscope Security Operations Center (KSOC) which allows real-time data access, a service accessible to all its clients.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: